A Population-Based, Retrospective Cohort Study Assessing Treatment Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Treated with Abiraterone, Enzalutamide, Docetaxel, or Cabazitaxel

Trial Profile

A Population-Based, Retrospective Cohort Study Assessing Treatment Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Treated with Abiraterone, Enzalutamide, Docetaxel, or Cabazitaxel

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Nov 2017 Results published in the Urology
    • 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association.
    • 21 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top